Skip to main content
Biosimilars
Oncologists’ Knowledge and Perspectives on the Use of Biosimilars
Read More
Biosimilars
A Successful Model of Biosimilar Adoption in a Community Oncology Practice
Read More
Biosimilars
Real-World Trends in Biosimilar Prescribing Among Oncology Providers
Read More
Biosimilars
Real-World Utilization and Cost Patterns with Biosimilar and Filgrastim Reference in a Community Oncology Setting
Read More
Biosimilars
Real-World Evidence of Bevacizumab-awwb Use in a Population of Patients with Cancer
Read More
Biosimilars
Same-Day Pegfilgrastim-cbqv Administration Is Feasible in Patients with Breast Cancer Receiving Myelosuppressive Chemotherapy Regimens
Read More
Biosimilars
Real-World Evidence of Cardiac Safety of Trastuzumab Biosimilar Trastuzumab-anns in Breast Cancer
Read More
Biosimilars
Incidence of Hypertension and Proteinuria in Bevacizumab- and Bevacizumab Biosimilar-Treated Cohorts
Read More
Biosimilars
Cost-Efficiency Analysis of Switching from Reference Pegfilgrastim to Pegfilgrastim-jmdb
Read More
Biosimilars
Real-World Data Showed Comparable pCR Rates with Neoadjuvant Chemotherapy plus Trastuzumab-dkst versus Trastuzumab
Read More
Page 70 of 196
Results 691 - 700 of 1953